iCAN aims to improve outcomes and quality of life of cancer patients.
We do this through cutting-edge research focused on improving understanding in immuno-oncology, tumor microenvironment and development of disease resistance.
Our research projects leverage the iCAN discovery platform to identify new targets and solutions for diagnosing and treating cancer.
The iCAN discovery platform links molecular profiling of tumors with broader health data of cancer patients, acting as a catalyst for breakthrough research and technologies.
The scale of data – 15,000 samples across different cancer types will be profiled by 2026 – enables real impact and broad studies across different cancer types.
The platform will enable an improved understanding of the complex interplay between cancer cells and the host.
Our approach is to keep the patient in the focus in all activities in developing a research and innovation hub in digital precision cancer medicine.
At the center of the ecosystem is the iCAN discovery platform leveraged in collaborative partnerships among researchers and the life science industry.
In English: About 60 researchers, patients, their loved ones, and citizens interested in cancer research Read More »
iCAN supports the joint statement on RDI funding from the Academy of Finland Flagship projects. Read More »
Researchers at the Universities of Helsinki and Turku have developed a test to identify those Read More »
iCAN had a strong showing in Business Finland’s last Research to Business funding round. Four Read More »
